Earnings included compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 43 cents against a gain of 12 cents per share in the year-ago quarter.
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
A pioneering team at St Jude Children's Research Hospital in the US say they successfully treated a child diagnosed with SMA ...
Citi analyst David Lebowitz lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $67 and keeps a Buy rating on the ...
CompanyOverview\|NASDAQ:BIIB] Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares ...
Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a ...
During Q4, Ionis reported revenues of $227 million, 68.1% above the $135 million estimated by analysts. That positive surprise was attributed in part to the successful launch and commercialization of ...
Ionis Pharmaceuticals (NASDAQ:IONS) stock gains as company reports strong Q4 results fueled by new product rollouts like ...
The U.S. senator says bipartisan work and region’s talent has helped LI become a ‘mecca of health innovation and research’ ...
The cuts in funding to Cold Spring Harbor Laboratory are one of many being proposed to science and research centers across ...
A girl on Long Island is speaking out after a clinical trial for Spinal Muscular Atrophy was cut by President Trump ...
Hi friends! Shane here! I just wanted to quick put up some reflections on my day today. I got my 7th Spinraza injection and ...